NICE (the National Institute for Health and Care Excellence) have released for consultation, a new set of draft guidelines for healthcare …
NICE Consultation on Guidelines for Suspected Neurological ConditionsRead More
August 14, 2017 by abzali123
NICE (the National Institute for Health and Care Excellence) have released for consultation, a new set of draft guidelines for healthcare …
NICE Consultation on Guidelines for Suspected Neurological ConditionsRead More
August 14, 2017 by abzali123
Researchers at Cardiff University, in collaboration with biotechnology company PerkinElmer, have created a more reliable test to screen newborn babies …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is DevelopedRead More
August 9, 2017 by abzali123
Mitobridge, Inc., a pioneer in the discovery and development of products that improve mitochondrial function, today announces a key milestone with the …
Mitobridge’s Potential Treatment for Duchenne Advances into Clinical DevelopmentRead More
August 9, 2017 by abzali123
The med-tech biopharmaceutical company, SOM Biotech, has granted a licence agreement with Corino Therapeutics Inc. for its first product SOMO266 for …
Worldwide licence for new drug SOMO266 as SOM Biotech expands to the United StatesRead More
August 1, 2017 by abzali123
A new study has started at Queen’s University Belfast. They are looking for young people aged 16-24 with a life-limiting condition and who …
July 25, 2017 by abzali123
In the fifth interview of the series “Portrait of Duchenne”, our Canadian partners La Fondation La Force talked with Joanne …
July 25, 2017 by abzali123
In this, the sixth interview in the series Portrait of Duchenne, our Canadian partners La Fondation La Force talked with Steve Winder at the Action …
July 25, 2017 by abzali123
Summit are looking for feedback from caregivers and patients themselves in their commitment to working alongside patients, their families …
Give your feedback to Summit in their Utrophin modulator patient/family surveyRead More
July 25, 2017 by abzali123
The likelihood of having a comorbid mental health condition is higher for neurology patients than for the long-term conditions patient population …
July 18, 2017 by abzali123
Sarepta and BioMarin have executed a license agreement that provides Sarepta Therapeutics with global exclusive rights to BioMarin’s Duchenne muscular …
Sarepta and BioMarin resolve exon skipping patent litigationRead More
June 22, 2017 by abzali123
Over a number of years we have worked with Santhera Pharmaceuticals and other Duchenne charities in relation to Santhera’s Phase III Clinical Trial …
What Raxone being given approval through the EAMS scheme means for the Duchenne communityRead More
June 22, 2017 by abzali123
We are excited to share with the Duchenne community, that Santhera Pharmaceutical’s drug Raxone, is the first Duchenne drug approved via the Early …
Raxone is the first Duchenne drug approved through the Early Access to Medicines SchemeRead More
Action Duchenne
Wellesley House
Duke of Wellington Avenue Royal Arsenal
London
SE18 6SS
07535 498 506
info@actionduchenne.org